Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29591762 | 1.00 | NR4A2 (0.50) | NR4A2PLAUMRGPRX4CFDSSTR5 | |
| SCHEMBL29852680 | 0.91 | LOXL2 (0.46) | NR4A2PLAUMRGPRX4CFDSSTR5 | |
| SCHEMBL23218806 | 0.91 | LOXL2 (0.46) | NR4A2PLAUMRGPRX4CFDSSTR5 | |
| SCHEMBL23218710 | 0.89 | CFD (0.50) | NR4A2PLAUCFDSSTR5NR1H4 | |
| SCHEMBL23218903 | 0.86 | CFD (0.42) | PLAUCFDSSTR5 | |
| SCHEMBL23219231 | 0.84 | PLG (0.46) | PLAUCFDF2 | |
| SCHEMBL28736134 | 0.82 | MRGPRX4 (0.48) | NR4A2MRGPRX4SSTR5NR4A1NR4A3 | |
| SCHEMBL29592507 | 0.81 | CFD (0.46) | PLAUCFD | |
| SCHEMBL23218914 | 0.81 | CFD (0.46) | PLAUCFD | |
| SCHEMBL23219211 | 0.81 | CFD (0.62) | PLAUCFDF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |